Allenex sells Anamar

IDRx is a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.

Before Christmas Finnish Combinostics announced that it has entered an agreement with the Swedish company SyntheticMR where SyntheticMR will acquire all shares in Combinostics.

Ultimovacs and Zelluna Immunotherapy have announced that Ultimovacs and shareholders of Zelluna representing more than 99% of the total number of issued and outstanding shares in Zelluna have entered into a definitive business combination agreement to combine the two companies in a share exchange transaction.

The transaction is valued at approximately USD 2.6 billion equity value and USD 2.5 billion net of cash, on a fully diluted basis.

Getinge has announced an agreement to acquire 100% of Paragonix Technologies for an aggregated purchase price, including upfront and earn out payments, estimated to approximately USD 477 million. The acquisition aligns with Getinge’s broader strategy to expand its portfolio into high growth markets that complement and enhance its acute heart and lung support offering already […]

The acquisition aligns with Labquality’s international growth strategy and enables Labquality to grow its business in Sweden and to enter new markets like Norway and Denmark, it states. “Scandinavian CRO is a great addition to our Labquality family completing our CRO business platform. Now, we are a full service CRO company, and we can continue […]

Genovis has announced the successful divestment of its antibody business to Leinco Technologies, a developer of antibodies for research and diagnostics. The divestment follows a strategic review by Genovis, which identified the need to concentrate on its core enzyme business, it states. The antibody business, while valuable, was deemed non-core to the company’s long-term growth […]